February 25, 2015, Outcome Capital is pleased to announce that Medtronic has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Outcome Capital served as exclusive financial advisor to Advanced Uro-Solutions.
Advanced Uro-Solutions develops and manufactures the NURO(TM) percutaneous tibial nerve stimulation system, which consists of a small external stimulator and a single, reusable lead to provide temporary stimulation to the tibial nerve. This therapy is 510(k) cleared by the FDA to treat patients with overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medtronic is preparing to launch the NURO system in the U.S. within the next 12 months.
More than 37 million adults in the United States – one in six – suffer from OAB. By 2018, it is estimated that 546 million people worldwide will be affected by OAB.
“The acquisition of Advanced Uro-Solutions expands Medtronic’s portfolio of treatment options for those suffering from chronic symptoms of overactive bladder,” said Linnea Burman, vice president and general manager, gastro/urology therapies at Medtronic. “Medtronic continues to invest in fully-implantable bladder control and bowel control therapies, and the addition of the NURO system to our existing portfolio of products will introduce more people suffering from bladder control issues to the benefits of neuromodulation.”
Since 2009, Advanced Uro-Solutions has been led by two founders, Dr. Brent Laing and Dr. John Green. “Studies show that roughly 80 percent of patients prescribed oral medications to treat their OAB symptoms have stopped taking them at 12 months, and Medtronic shares our commitment to advancing neuromodulation and increasing patient access to advanced solutions intended to treat their symptoms,” said Dr. John Green, former chairman and CEO of Advanced Uro-Solutions. “We are excited to take this step toward making this important therapy available to patients around the world.”
About Outcome Capital – outcomecapital.wpengine.com
Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, healthcare services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services. The firm utilizes its proven approach to value enhancement by assisting boards and management teams in navigating both the financial and strategic markets and in implementing the best path for success. Outcome Capital’s strength stems from its unique ability to draw on its wide range of operational, strategic and private equity experience, its expertise across the value building life-cycle and its broad industry relationships. The professionals at Outcome Capital take pride in their ability to help their clients to make well-informed strategic decisions and recognize the full value created by their vision.
The collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies Boston & Shanghai – September 14, 2023. Outcome Capital, a specialized life science advisory and investment banking firm, and YAFO Capital, a Shanghai-based boutique investment banking and advisory firm, announced that the companies […]Read More
Outcome Capital Life Science Market Pulse August 2023 Click to view our LifeSciences Pulse NewsletterDownload